Abstract:Photodynamic therapy is a minimally invasive procedure used in the treatment of several diseases, including some types of cancer. It is based on photosensitizer molecules, which, in the presence of oxygen and light, lead to the formation of reactive oxygen species (ROS) and consequent cell death. The selection of the photosensitizer molecule is important for the therapy efficiency; therefore, many molecules such as dyes, natural products and metallic complexes have been investigated regarding their photosensitizing potential. In this work, the phototoxic potential of the DNA-intercalating molecules-the dyes methylene blue (MB), acridine orange (AO) and gentian violet (GV); the natural products curcumin (CUR), quercetin (QT) and epigallocatechin gallate (EGCG); and the chelating compounds neocuproine (NEO), 1,10-phenanthroline (PHE) and 2,2'-bipyridyl (BIPY)-were analyzed. The cytotoxicity of these chemicals was tested in vitro in non-cancer keratinocytes (HaCaT) and squamous cell carcinoma (MET1) cell lines. A phototoxicity assay and the detection of intracellular ROS were performed in MET1 cells. Results revealed that the IC50 values of the dyes and curcumin in MET1 cells were lower than 30 µM, while the values for the natural products QT and EGCG and the chelating agents BIPY and PHE were higher than 100 µM. The IC50 of MB and AO was greatly affected by irradiation when submitted to 640 nm and 457 nm light sources, respectively. ROS detection was more evident for cells treated with AO at low concentrations. In studies with the melanoma cell line WM983b, cells were more resistant to MB and AO and presented slightly higher IC50 values, in line with the results of the phototoxicity assays. This study reveals that many molecules can act as photosensitizers, but the effect depends on the cell line and the concentration of the chemical. Finally, significant photosensitizing activity of acridine orange at low concentrations and moderate light doses was demonstrated.

Psoralen derivatives and longwave ultraviolet irradiation are active in vitro against human melanoma cell line

UVA radiation augments cytotoxic activity of psoralens in melanoma cells

Study on Regulation of Melanogenesis Induced by 8-Methoxypsoralen and Related Signal Transduction Pathways in Murine Melanoma Cells

Quantitative Analysis of DNA Interstrand Cross-Links and Monoadducts Formed in Human Cells Induced by Psoralens and UVA Irradiation.

Phototoxic Potential of Different DNA Intercalators for Skin Cancer Therapy: In Vitro Screening

In Vitro Effects of 8-Methoxypsoralen on the Adhesion and Matrix Metalloproteinase-2 Expression of Melanocytes

Psoralen Derivatives with Enhanced Potency

Novel sulfonamide porphyrin TBPoS-2OH used in photodynamic therapy for malignant melanoma

Photodynamic therapy in melanoma--an update

Psoralen: a narrative review of current and future therapeutic uses

8-Methoxypsoralen Induces Apoptosis by Upregulating p53 and Inhibits Metastasis by Downregulating MMP-2 and MMP-9 in Human Gastric Cancer Cells

5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal, mutagenic and clastogenic properties

Acute Skin Lesions Following Psoralen Plus Ultraviolet A Radiation Investigated by Optical Coherence Tomography

Resistance to ursolic acid-induced apoptosis through involvement of melanogenesis and COX-2/PGE2 pathways in human M4Beu melanoma cancer cells

Study of Melanogenesis and MDA on the Animal Models of Leukodermia Induced by Psoralen Liposome Gel

Direct and Abscopal Antitumor Responses Elicited by AlPcNE-Mediated Photodynamic Therapy in a Murine Melanoma Model

Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro

Antiproliferative activity of 8-methoxypsoralen on DU145 prostate cancer cells under UVA and blue light

Verteporfin Induces Apoptosis and Eliminates Cancer Stem-Like Cells in Uveal Melanoma in the Absence of Light Activation.

Synthesis and Biological Evaluation of Glycosylated Psoralen Derivatives

Photodynamic Therapy in Melanoma - Where do we Stand?